Angelo Rosolen1, Sherrie L Perkins1, C Ross Pinkerton1, R Paul Guillerman1, John T Sandlund1, Catherine Patte1, Alfred Reiter1, Mitchell S Cairo2. 1. Angelo Rosolen, University of Padova, Padova, Italy; Sherrie L. Perkins, University of Utah Health Sciences Center, Salt Lake City, UT; C. Ross Pinkerton, University of Queensland, Brisbane, Queensland, Australia; R. Paul Guillerman, Texas Children's Hospital, Houston, TX; John T. Sandlund, St Jude Children's Research Hospital, Memphis, TN; Catherine Patte, Institut Gustave Roussy, Paris, France; Alfred Reiter, Justus-Liebig University of Giessen, Giessen, Germany; and Mitchell S. Cairo, New York Medical College, Valhalla, NY. 2. Angelo Rosolen, University of Padova, Padova, Italy; Sherrie L. Perkins, University of Utah Health Sciences Center, Salt Lake City, UT; C. Ross Pinkerton, University of Queensland, Brisbane, Queensland, Australia; R. Paul Guillerman, Texas Children's Hospital, Houston, TX; John T. Sandlund, St Jude Children's Research Hospital, Memphis, TN; Catherine Patte, Institut Gustave Roussy, Paris, France; Alfred Reiter, Justus-Liebig University of Giessen, Giessen, Germany; and Mitchell S. Cairo, New York Medical College, Valhalla, NY. mitchell_cairo@nymc.edu.
Abstract
PURPOSE: Treatment and prognosis of pediatric non-Hodgkin lymphoma (NHL) have improved dramatically in the last 30 years. However, the St Jude NHL staging classification for pediatric NHL was developed more than 35 years ago. The most recent Lugano lymphoma staging classification focused on adult lymphoma. Furthermore, major limitations of the current pediatric NHL staging classification include lack of consideration of new distinct pediatric NHL histologic entities; absence of recognition of frequent skin, bone, kidney, ovarian, and other organ involvement; and lack of newer precise methods to detect bone marrow and CNS involvement, minimal disease quantification, and highly sensitive imaging technologies. METHODS: An international multidisciplinary expert panel convened in Frankfurt, Germany, in 2009 at the Third International Childhood, Adolescent and Young Adult NHL Symposium to develop a revised international pediatric NHL staging system (IPNHLSS), addressing limitations of the current pediatric NHL staging system and creating a revised classification. Evidence-based disease distribution and behavior were reviewed from multiple pediatric cooperative group NHL studies. RESULTS: A revised IPNHLSS was developed incorporating new histologic entities, extranodal dissemination, improved diagnostic methods, and advanced imaging technology. CONCLUSION: This revised IPNHLSS will facilitate more precise staging for children and adolescents with NHL and facilitate comparisons of efficacy across different treatment strategies, various institutions, multicenter trials, and cooperative groups by allowing for reproducible pediatric-based staging at diagnosis and relapse.
PURPOSE: Treatment and prognosis of pediatric non-Hodgkin lymphoma (NHL) have improved dramatically in the last 30 years. However, the St Jude NHL staging classification for pediatric NHL was developed more than 35 years ago. The most recent Lugano lymphoma staging classification focused on adult lymphoma. Furthermore, major limitations of the current pediatric NHL staging classification include lack of consideration of new distinct pediatric NHL histologic entities; absence of recognition of frequent skin, bone, kidney, ovarian, and other organ involvement; and lack of newer precise methods to detect bone marrow and CNS involvement, minimal disease quantification, and highly sensitive imaging technologies. METHODS: An international multidisciplinary expert panel convened in Frankfurt, Germany, in 2009 at the Third International Childhood, Adolescent and Young Adult NHL Symposium to develop a revised international pediatric NHL staging system (IPNHLSS), addressing limitations of the current pediatric NHL staging system and creating a revised classification. Evidence-based disease distribution and behavior were reviewed from multiple pediatric cooperative group NHL studies. RESULTS: A revised IPNHLSS was developed incorporating new histologic entities, extranodal dissemination, improved diagnostic methods, and advanced imaging technology. CONCLUSION: This revised IPNHLSS will facilitate more precise staging for children and adolescents with NHL and facilitate comparisons of efficacy across different treatment strategies, various institutions, multicenter trials, and cooperative groups by allowing for reproducible pediatric-based staging at diagnosis and relapse.
Authors: T A Lister; D Crowther; S B Sutcliffe; E Glatstein; G P Canellos; R C Young; S A Rosenberg; C A Coltman; M Tubiana Journal: J Clin Oncol Date: 1989-11 Impact factor: 44.544
Authors: J C Gentet; C Patte; E Quintana; C Bergeron; H Rubie; F Pein; M C Demaille; T Philip; C Raybaud Journal: J Clin Oncol Date: 1990-04 Impact factor: 44.544
Authors: Mitchell S Cairo; Richard Sposto; Sherrie L Perkins; Anna T Meadows; Margo L Hoover-Regan; James R Anderson; Stuart E Siegel; Mark A Lones; Nicole Tedeschi-Blok; Marshall E Kadin; Carl R Kjeldsberg; John F Wilson; Warren Sanger; Erin Morris; Mark D Krailo; Jonathan L Finlay Journal: Br J Haematol Date: 2003-02 Impact factor: 6.998
Authors: Elaine Coustan-Smith; Jose Sancho; Michael L Hancock; Bassem I Razzouk; Raul C Ribeiro; Gaston K Rivera; Jeffrey E Rubnitz; John T Sandlund; Ching-Hon Pui; Dario Campana Journal: Blood Date: 2002-10-01 Impact factor: 22.113
Authors: L Mussolin; K Basso; M Pillon; E S D'Amore; A Lombardi; L Luzzatto; L Zanesco; A Rosolen Journal: Leukemia Date: 2003-03 Impact factor: 11.528
Authors: C Patte; T Philip; C Rodary; J M Zucker; H Behrendt; J C Gentet; J P Lamagnère; J Otten; D Dufillot; F Pein Journal: J Clin Oncol Date: 1991-01 Impact factor: 44.544
Authors: Mitchell S Cairo; Richard Sposto; Margo Hoover-Regan; Anna T Meadows; James R Anderson; Stuart E Siegel; Marshall E Kadin; Carl R Kjeldsberg; John F Wilson; Sherrie L Perkins; Mark A Lones; Erin Morris; Jonathan L Finlay Journal: Am J Hematol Date: 2003-01 Impact factor: 10.047
Authors: Jan Styczynski; Walter van der Velden; Christopher P Fox; Dan Engelhard; Rafael de la Camara; Catherine Cordonnier; Per Ljungman Journal: Haematologica Date: 2016-07 Impact factor: 9.941
Authors: Véronique Minard-Colin; Laurence Brugières; Alfred Reiter; Mitchell S Cairo; Thomas G Gross; Wilhelm Woessmann; Birgit Burkhardt; John T Sandlund; Denise Williams; Marta Pillon; Keizo Horibe; Anne Auperin; Marie-Cécile Le Deley; Martin Zimmerman; Sherrie L Perkins; Martine Raphael; Laurence Lamant; Wolfram Klapper; Lara Mussolin; Hélène A Poirel; Elizabeth Macintyre; Christine Damm-Welk; Angelo Rosolen; Catherine Patte Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544